decibel partnership cocoon

Decibel Therapeutics and Cocoon Biotech Announce Research Collaboration

BOSTON, MASSACHUSETTS — Biotech startup, Decibel Therapeutics, has announced a research collaboration with Cocoon Biotech to apply Cocoon’s proprietary silk fibroin platform to the development of therapeutics for hearing and balance disorders.

According to the announcement, the companies will jointly conduct research into drug formulations optimized for transtympanic delivery to the ear, and Decibel will receive an option to exclusively license the technology on a program-by-program basis. For each licensed program, Cocoon will receive an upfront license fee, as well as development milestone payments and downstream royalties on programs that advance.

“Our silk fibroin platform has the potential to transform our ability to formulate, deliver, and stabilize molecules across a range of therapeutic applications in human health, animal health, consumer products, and agriculture, with resulting improvements in manufacturing processes, safety, and efficacy. We are excited to work with Decibel in applying this technology to hearing and balance disorders.”

Ailis Tweed-Kent, MD, CEO of Cocoon

“The unique properties of silk protein as an excipient offer the potential for the prolonged and controlled release of a therapeutic compound into the middle ear, where it can then be absorbed into the inner ear,” said John Lee, executive vice president of pharmaceutical development at Decibel. “In those instances where transtympanic delivery of a drug is the right approach, we believe that Cocoon’s platform has the potential to maximize therapeutic exposure of our medications while minimizing the frequency of injections.”

 

Source: Decibel Therapeutics, Cocoon Biotech


1 Comment

Leave a Reply

Your email address will not be published.